Stem Cells 
CAR-T 
AAV Delivery 
LVV Delivery 
Other Viral Vectors 
Extracellular Vesicles 
Nanoparticles 
Who We Are
Artis BioSolutions is a Synthetic DNA and Advanced Therapy Platform
We build the DNA that powers genetic medicine and translate it into clinical grade therapies through integrated manufacturing.
The advanced therapy industry has relied on fragmented supply chains, legacy plasmid DNA, and disconnected vendors to move therapies from genetic concept to the clinic. Artis was built to replace that model with the first integrated platform to combine proprietary enzymatic synthetic DNA production with advanced therapy development and GMP manufacturing, with operations in the United States and the European Union.
Synthetic DNA
Our oDNA Technology
Truly synthetic oDNA, with your gene of interest enzymatically produced to gram scale and free of biological contamination, is the superior starting material for every application in genetic medicine. With uniquely optimized formats designed with program end-goals in mind, oDNA is built for evolving therapeutic approaches.
Key Capabilities
Truly Synthetic oDNA
RUO and GMP grades, no plasmid dependency at any stage
2-Week Production Timelines
2 weeks for RUO and only 3-4 weeks for GMP
Application-Optimized Formats
Linear dsDNA with your GOI and specialized adapters
US and EU Production
GMP and RUO manufacturing in Watertown, MA and Bilbao, Spain
Up to Gram Scale
Supporting mRNA, gene editing, viral vectors, cell therapies, vaccines, and emerging biologics
Modalities
Supporting Multiple Advanced Therapy Modalities on One Platform
Because we control the starting material, we can optimize the entire downstream path. Our platform supports the broadest range of advanced therapy modalities from a single, integrated infrastructure.
Services
An Integrated Solution from Starting Material Through Commercialization
Artis provides fully integrated services with disciplined, end-to-end execution to accelerate advanced therapy medicinal products (ATMPs) from synthetic DNA through GMP manufacturing, all within a single quality framework. Our model eliminates the handoffs, vendor transitions, and knowledge loss that slow programs down.
We offer flexible engagement models
From defined-scope execution to deep co-development partnerships, enabling teams to engage Artis at any stage of development and scale efficiently as programs evolve, accelerating progression to the next milestone with close collaboration, seamless technology transfer, and continuity from development through GMP manufacturing.
Latest News
Artis Insights
One Roof, Two Capabilities: Why Synthetic DNA + AAV Manufacturing Belongs Together
AAV is one of the most widely used delivery platforms in gene therapy, supporting approved treatments for inherited retinal diseases, spinal muscular atrophy, hemophilia, and a growing number of clinical-stage programs.
18 June 2026Read More
Artis Insights
From Bespoke to Off-the-Shelf: The Manufacturing Reckoning Behind CAR-T’s Hottest Race
In vivo CAR-T, once a distant technology, is now the most promising frontier in the quest to scale up cell and gene therapy, and the questions it raises are, once again, manufacturing questions.
28 May 2026
Read More
Artis Insights
Extracellular Vesicles: The Next Frontier in Non-Viral Therapeutic Delivery
Extracellular vesicles have been a subject of scientific fascination for decades. For most of that time, they were studied primarily as mediators of intercellular communication – natural couriers shuttling proteins, nucleic acids, lipids, and metabolites between cells.
26 Feb 2026Read More